# Fumio Imamura

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/fumio-imamura/

## Facts

| Field | Value |
| --- | --- |
| Citations | 23,512 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 56 |
| i10-index | 140 |
| Last Known Institution | Tokyo Medical and Dental University |
| OpenAlex ID | https://openalex.org/A5047714811 |
| ORCID iD | https://orcid.org/0009-0009-5961-2101 |
| Works | 399 |

## Researcher papers

- [Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-untreated-i-egfr-i-mutated-advanced-non-small-cell-lung-cancer/)
- [Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-untreated-i-egfr-i-mutated-advanced-nsclc/)
- [Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial](https://scholariq.org/papers/alectinib-versus-crizotinib-in-patients-with-alk-positive-non-small-cell-lung/)
- [Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-erlotinib-in-patients-with-untreated-egfr-mutated-advanced-non/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)
- [Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-study-v-15-32-of-gefitinib-versus-docetaxel-in-previously-treated/)
- [Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study](https://scholariq.org/papers/mechanisms-of-acquired-resistance-to-first-line-osimertinib-preliminary-data/)
- [Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-untreated-egfr-mutated-advanced-nsclc/)
- [Clinical Efficacy and Safety of Nivolumab: Results of a <u>M</u> ulticenter, Op <u>e</u> n-label, Single-a <u>r</u> m, Japanese Phase II study in Mal <u>i</u> gnant Pleural Meso <u>t</u> helioma (MERIT)](https://scholariq.org/papers/clinical-efficacy-and-safety-of-nivolumab-results-of-a-u-m-u-ulticenter-op-u-e-u/)
- [Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L](https://scholariq.org/papers/randomized-phase-iii-study-comparing-gefitinib-with-erlotinib-in-patients-with/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Tokyo Medical and Dental University](https://scholariq.org/institutions/tokyo-medical-and-dental-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.